Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Music-Enhanced Analgesia and Antiseizure Activities in Animal Models of Pain and Epilepsy: Toward Preclinical Studies Supporting Development of Digital Therapeutics and Their Combinations With Pharmaceutical Drugs.

Metcalf CS, Huntsman M, Garcia G, Kochanski AK, Chikinda M, Watanabe E, Underwood T, Vanegas F, Smith MD, White HS, Bulaj G.

Front Neurol. 2019 Mar 27;10:277. doi: 10.3389/fneur.2019.00277. eCollection 2019.

2.

Improving Self-Esteem With Motivational Quotes: Opportunities for Digital Health Technologies for People With Chronic Disorders.

Bedrov A, Bulaj G.

Front Psychol. 2018 Nov 2;9:2126. doi: 10.3389/fpsyg.2018.02126. eCollection 2018. No abstract available.

3.

Mobile Software as a Medical Device (SaMD) for the Treatment of Epilepsy: Development of Digital Therapeutics Comprising Behavioral and Music-Based Interventions for Neurological Disorders.

Afra P, Bruggers CS, Sweney M, Fagatele L, Alavi F, Greenwald M, Huntsman M, Nguyen K, Jones JK, Shantz D, Bulaj G.

Front Hum Neurosci. 2018 May 1;12:171. doi: 10.3389/fnhum.2018.00171. eCollection 2018.

4.

A Prototype Exercise-Empowerment Mobile Video Game for Children With Cancer, and Its Usability Assessment: Developing Digital Empowerment Interventions for Pediatric Diseases.

Bruggers CS, Baranowski S, Beseris M, Leonard R, Long D, Schulte E, Shorter A, Stigner R, Mason CC, Bedrov A, Pascual I, Bulaj G.

Front Pediatr. 2018 Apr 9;6:69. doi: 10.3389/fped.2018.00069. eCollection 2018.

5.

Commentary: A Breathing-Based Meditation Intervention for Patients with Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study.

McKennon S, Levitt SE, Bulaj G.

Front Med (Lausanne). 2017 Apr 6;4:37. doi: 10.3389/fmed.2017.00037. eCollection 2017. No abstract available.

6.

The novel anticonvulsant neuropeptide and galanin analogue, NAX-5055, does not alter energy and amino acid metabolism in cultured brain cells.

Aldana BI, Waagepetersen HS, Schousboe A, White HS, Bulaj G, Walls AB.

J Neurosci Res. 2017 Nov;95(11):2286-2296. doi: 10.1002/jnr.24057. Epub 2017 Apr 11.

PMID:
28397993
7.

Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.

Metcalf CS, Smith MD, Klein BD, McDougle DR, Zhang L, Bulaj G.

Neurochem Res. 2017 Jul;42(7):1983-1994. doi: 10.1007/s11064-017-2229-5. Epub 2017 Apr 6.

8.

Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics.

Metcalf CS, Klein BD, McDougle DR, Zhang L, Kaufmann D, Bulaj G, White HS.

Epilepsia. 2017 Feb;58(2):239-246. doi: 10.1111/epi.13647. Epub 2017 Jan 18.

9.
10.
11.

The anticonvulsant action of the galanin receptor agonist NAX-5055 involves modulation of both excitatory- and inhibitory neurotransmission.

Walls AB, Flynn SP, West PJ, Müller MS, Bak LK, Bulaj G, Schousboe A, White HS.

Epilepsy Res. 2016 Mar;121:55-63. doi: 10.1016/j.eplepsyres.2016.01.006. Epub 2016 Jan 27.

PMID:
26894875
12.

Structural Basis for the Inhibition of Voltage-gated Sodium Channels by Conotoxin μO§-GVIIJ.

Green BR, Gajewiak J, Chhabra S, Skalicky JJ, Zhang MM, Rivier JE, Bulaj G, Olivera BM, Yoshikami D, Norton RS.

J Biol Chem. 2016 Mar 25;291(13):7205-20. doi: 10.1074/jbc.M115.697672. Epub 2016 Jan 27.

13.

Clinical and Neurobiological Perspectives of Empowering Pediatric Cancer Patients Using Videogames.

Govender M, Bowen RC, German ML, Bulaj G, Bruggers CS.

Games Health J. 2015 Oct;4(5):362-74. doi: 10.1089/g4h.2015.0014. Epub 2015 Jun 26.

14.

Probing the Redox States of Sodium Channel Cysteines at the Binding Site of μO§-Conotoxin GVIIJ.

Zhang MM, Gajewiak J, Azam L, Bulaj G, Olivera BM, Yoshikami D.

Biochemistry. 2015 Jun 30;54(25):3911-20. doi: 10.1021/acs.biochem.5b00390. Epub 2015 Jun 18.

PMID:
26039939
15.

A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties.

Lee HK, Zhang L, Smith MD, Walewska A, Vellore NA, Baron R, McIntosh JM, White HS, Olivera BM, Bulaj G.

Front Pharmacol. 2015 Feb 10;6:11. doi: 10.3389/fphar.2015.00011. eCollection 2015.

16.

Structure and function of μ-conotoxins, peptide-based sodium channel blockers with analgesic activity.

Green BR, Bulaj G, Norton RS.

Future Med Chem. 2014 Oct;6(15):1677-98. doi: 10.4155/fmc.14.107. Review.

17.

Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models.

Metcalf CS, Klein BD, McDougle DR, Zhang L, Smith MD, Bulaj G, White HS.

J Pharmacol Exp Ther. 2015 Jan;352(1):185-93. doi: 10.1124/jpet.114.219063. Epub 2014 Oct 27.

18.
19.

Interactions of disulfide-deficient selenocysteine analogs of μ-conotoxin BuIIIB with the α-subunit of the voltage-gated sodium channel subtype 1.3.

Green BR, Zhang MM, Chhabra S, Robinson SD, Wilson MJ, Redding A, Olivera BM, Yoshikami D, Bulaj G, Norton RS.

FEBS J. 2014 Jul;281(13):2885-98. doi: 10.1111/febs.12835. Epub 2014 Jun 9.

20.

From molecular phylogeny towards differentiating pharmacology for NMDA receptor subtypes.

Platt RJ, Curtice KJ, Twede VD, Watkins M, Gruszczyński P, Bulaj G, Horvath MP, Olivera BM.

Toxicon. 2014 Apr;81:67-79. doi: 10.1016/j.toxicon.2014.01.016. Epub 2014 Feb 7.

21.

A disulfide tether stabilizes the block of sodium channels by the conotoxin μO§-GVIIJ.

Gajewiak J, Azam L, Imperial J, Walewska A, Green BR, Bandyopadhyay PK, Raghuraman S, Ueberheide B, Bern M, Zhou HM, Minassian NA, Hagan RH, Flinspach M, Liu Y, Bulaj G, Wickenden AD, Olivera BM, Yoshikami D, Zhang MM.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2758-63. doi: 10.1073/pnas.1324189111. Epub 2014 Feb 4.

22.

On the importance of oxidative folding in the evolution of conotoxins: cysteine codon preservation through gene duplication and adaptation.

Steiner AM, Bulaj G, Puillandre N.

PLoS One. 2013 Nov 11;8(11):e78456. doi: 10.1371/journal.pone.0078456. eCollection 2013.

23.

Expanding chemical diversity of conotoxins: peptoid-peptide chimeras of the sodium channel blocker μ-KIIIA and its selenopeptide analogues.

Walewska A, Han TS, Zhang MM, Yoshikami D, Bulaj G, Rolka K.

Eur J Med Chem. 2013 Jul;65:144-50. doi: 10.1016/j.ejmech.2013.04.041. Epub 2013 May 1.

24.

Mammalian neuronal sodium channel blocker μ-conotoxin BuIIIB has a structured N-terminus that influences potency.

Kuang Z, Zhang MM, Gupta K, Gajewiak J, Gulyas J, Balaram P, Rivier JE, Olivera BM, Yoshikami D, Bulaj G, Norton RS.

ACS Chem Biol. 2013;8(6):1344-51. doi: 10.1021/cb300674x. Epub 2013 Apr 16.

25.

Pharmacological fractionation of tetrodotoxin-sensitive sodium currents in rat dorsal root ganglion neurons by μ-conotoxins.

Zhang MM, Wilson MJ, Gajewiak J, Rivier JE, Bulaj G, Olivera BM, Yoshikami D.

Br J Pharmacol. 2013 May;169(1):102-14. doi: 10.1111/bph.12119.

26.

Incorporation of monodisperse oligoethyleneglycol amino acids into anticonvulsant analogues of galanin and neuropeptide y provides peripherally acting analgesics.

Zhang L, Klein BD, Metcalf CS, Smith MD, McDougle DR, Lee HK, White HS, Bulaj G.

Mol Pharm. 2013 Feb 4;10(2):574-85. doi: 10.1021/mp300236v. Epub 2013 Jan 15.

PMID:
23259957
27.

Cyclic analogs of galanin and neuropeptide Y by hydrocarbon stapling.

Green BR, Klein BD, Lee HK, Smith MD, Steve White H, Bulaj G.

Bioorg Med Chem. 2013 Jan 1;21(1):303-10. doi: 10.1016/j.bmc.2012.10.026. Epub 2012 Oct 30.

PMID:
23176753
28.

Distinct disulfide isomers of μ-conotoxins KIIIA and KIIIB block voltage-gated sodium channels.

Khoo KK, Gupta K, Green BR, Zhang MM, Watkins M, Olivera BM, Balaram P, Yoshikami D, Bulaj G, Norton RS.

Biochemistry. 2012 Dec 11;51(49):9826-35. doi: 10.1021/bi301256s. Epub 2012 Nov 28.

29.

Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature.

Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian KD, Fischbach MA, Garavelli JS, Göransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Müller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJ, Rebuffat S, Ross RP, Sahl HG, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süssmuth RD, Tagg JR, Tang GL, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA.

Nat Prod Rep. 2013 Jan;30(1):108-60. doi: 10.1039/c2np20085f. Review.

30.

Co-expression of Na(V)β subunits alters the kinetics of inhibition of voltage-gated sodium channels by pore-blocking μ-conotoxins.

Zhang MM, Wilson MJ, Azam L, Gajewiak J, Rivier JE, Bulaj G, Olivera BM, Yoshikami D.

Br J Pharmacol. 2013 Apr;168(7):1597-610. doi: 10.1111/bph.12051.

31.

Patient-empowerment interactive technologies.

Bruggers CS, Altizer RA, Kessler RR, Caldwell CB, Coppersmith K, Warner L, Davies B, Paterson W, Wilcken J, D'Ambrosio TA, German ML, Hanson GR, Gershan LA, Korenberg JR, Bulaj G.

Sci Transl Med. 2012 Sep 19;4(152):152ps16.

PMID:
22993292
32.

Modulation of conotoxin structure and function is achieved through a multienzyme complex in the venom glands of cone snails.

Safavi-Hemami H, Gorasia DG, Steiner AM, Williamson NA, Karas JA, Gajewiak J, Olivera BM, Bulaj G, Purcell AW.

J Biol Chem. 2012 Oct 5;287(41):34288-303. doi: 10.1074/jbc.M112.366781. Epub 2012 Aug 13.

33.

Dissecting a role of evolutionary-conserved but noncritical disulfide bridges in cysteine-rich peptides using ω-conotoxin GVIA and its selenocysteine analogs.

Gowd KH, Blais KD, Elmslie KS, Steiner AM, Olivera BM, Bulaj G.

Biopolymers. 2012;98(3):212-23. doi: 10.1002/bip.22047.

34.

Selective purification of recombinant neuroactive peptides using the flagellar type III secretion system.

Singer HM, Erhardt M, Steiner AM, Zhang MM, Yoshikami D, Bulaj G, Olivera BM, Hughes KT.

MBio. 2012 May 29;3(3). pii: e00115-12. doi: 10.1128/mBio.00115-12. Print 2012.

35.

Conantokins derived from the Asprella clade impart conRl-B, an N-methyl d-aspartate receptor antagonist with a unique selectivity profile for NR2B subunits.

Gowd KH, Han TS, Twede V, Gajewiak J, Smith MD, Watkins M, Platt RJ, Toledo G, White HS, Olivera BM, Bulaj G.

Biochemistry. 2012 Jun 12;51(23):4685-92. doi: 10.1021/bi300055n. Epub 2012 May 30.

36.

Stapling mimics noncovalent interactions of γ-carboxyglutamates in conantokins, peptidic antagonists of N-methyl-D-aspartic acid receptors.

Platt RJ, Han TS, Green BR, Smith MD, Skalicky J, Gruszczynski P, White HS, Olivera B, Bulaj G, Gajewiak J.

J Biol Chem. 2012 Jun 8;287(24):20727-36. doi: 10.1074/jbc.M112.350462. Epub 2012 Apr 19.

37.

Reagentless oxidative folding of disulfide-rich peptides catalyzed by an intramolecular diselenide.

Steiner AM, Woycechowsky KJ, Olivera BM, Bulaj G.

Angew Chem Int Ed Engl. 2012 Jun 4;51(23):5580-4. doi: 10.1002/anie.201200062. Epub 2012 Mar 27. No abstract available.

38.

Converting peptides into drug leads by lipidation.

Zhang L, Bulaj G.

Curr Med Chem. 2012;19(11):1602-18. Review.

PMID:
22376031
39.

Generating orally active galanin analogues with analgesic activities.

Robertson CR, Pruess TH, Grussendorf E, White HS, Bulaj G.

ChemMedChem. 2012 May;7(5):903-9. doi: 10.1002/cmdc.201100574. Epub 2012 Feb 28.

40.

Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA.

Khoo KK, Wilson MJ, Smith BJ, Zhang MM, Gulyas J, Yoshikami D, Rivier JE, Bulaj G, Norton RS.

J Med Chem. 2011 Nov 10;54(21):7558-66. doi: 10.1021/jm200839a. Epub 2011 Oct 12.

41.

μ-Conotoxins that differentially block sodium channels NaV1.1 through 1.8 identify those responsible for action potentials in sciatic nerve.

Wilson MJ, Yoshikami D, Azam L, Gajewiak J, Olivera BM, Bulaj G, Zhang MM.

Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10302-7. doi: 10.1073/pnas.1107027108. Epub 2011 Jun 7.

42.

Navβ subunits modulate the inhibition of Nav1.8 by the analgesic gating modifier μO-conotoxin MrVIB.

Wilson MJ, Zhang MM, Azam L, Olivera BM, Bulaj G, Yoshikami D.

J Pharmacol Exp Ther. 2011 Aug;338(2):687-93. doi: 10.1124/jpet.110.178343. Epub 2011 May 17.

43.

Anticonvulsant neuropeptides as drug leads for neurological diseases.

Robertson CR, Flynn SP, White HS, Bulaj G.

Nat Prod Rep. 2011 Apr;28(4):741-62. doi: 10.1039/c0np00048e. Epub 2011 Feb 21. Review.

PMID:
21340067
44.

Analgesic neuropeptide W suppresses seizures in the brain revealed by rational repositioning and peptide engineering.

Green BR, Smith M, White KL, White HS, Bulaj G.

ACS Chem Neurosci. 2011 Jan 19;2(1):51-6. doi: 10.1021/cn1000974. Epub 2010 Nov 18. Review.

45.

Circular logic: nonribosomal peptide-like macrocyclization with a ribosomal peptide catalyst.

McIntosh JA, Robertson CR, Agarwal V, Nair SK, Bulaj GW, Schmidt EW.

J Am Chem Soc. 2010 Nov 10;132(44):15499-501. doi: 10.1021/ja1067806.

46.

Selenopeptide analogs of EETI-II retain potent trypsin inhibitory activities.

Walewska A, Jaśkiewicz A, Bulaj G, Rolka K.

Chem Biol Drug Des. 2011 Jan;77(1):93-7. doi: 10.1111/j.1747-0285.2010.01046.x. Epub 2010 Oct 19.

PMID:
20958922
47.
48.

Disulfide-Depleted Selenoconopeptides: a Minimalist Strategy to Oxidative Folding of Cysteine-Rich Peptides.

Han TS, Zhang MM, Gowd KH, Walewska A, Yoshikami D, Olivera BM, Bulaj G.

ACS Med Chem Lett. 2010 May 3;1(4):140-144.

49.

Introduction of lipidization-cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities.

Green BR, White KL, McDougle DR, Zhang L, Klein B, Scholl EA, Pruess TH, White HS, Bulaj G.

J Pept Sci. 2010 Sep;16(9):486-95. doi: 10.1002/psc.1266.

PMID:
20645434
50.

Characterization of conantokin Rl-A: molecular phylogeny as structure/function study.

Gowd KH, Watkins M, Twede VD, Bulaj GW, Olivera BM.

J Pept Sci. 2010 Aug;16(8):375-82. doi: 10.1002/psc.1249.

Supplemental Content

Support Center